Eleven Therapeutics utilizes synthetic chemistry and AI algorithms to develop RNA therapeutics that optimize safety, efficiency, and duration of effect. Their platform maps the vast chemical space of RNA molecules, addressing the need for precise and effective therapeutic solutions in the rapidly evolving field of RNA-based medicine.
Funding
$18M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The therapeutic potential of RNA is limited by challenges in optimizing its safety, efficiency, and duration of effect within the body. Mapping the vast chemical space of RNA molecules to identify optimal candidates for specific therapeutic applications is a complex and resource-intensive process.
Solution
Eleven Therapeutics employs synthetic chemistry and artificial intelligence (AI) algorithms to design and develop next-generation RNA therapeutics. Their platform leverages massively parallel combinatorial chemistry to explore the chemical space of RNA molecules and identify structure-activity relationships (SAR). By integrating big data and AI, the platform optimizes RNA molecules for improved safety profiles, enhanced therapeutic efficacy, and prolonged duration of action. This approach enables the creation of precise and effective RNA-based medicines.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking advanced RNA therapeutics for various disease indications.
Features
- Massively parallel combinatorial chemistry for efficient exploration of RNA chemical space
- AI-driven algorithms to predict and optimize RNA molecule properties
- Data-driven approach to enhance safety, efficacy, and duration of effect
- Digital design and optimization of RNA molecules
- Identification of structure-activity relationships (SAR) for targeted therapeutic applications